RMC No. 27-2026: Updated FDA List of VAT-Exempt Drugs for Cancer, Diabetes, Hypertension, and Other Illnesses

RMC No. 27-2026 updates the FDA-endorsed VAT-exempt drug list for cancer, diabetes, hypertension, kidney disease, mental illness, and more. Businesses selling covered medicines must immediately check whether their pharmacy, hospital, distribution, accounting, and point-of-sale systems reflect the updated VAT-exempt drug list endorsed by the Food and Drug Administration. RMC No. 27-2026 publishes the updated full […]

RMC No. 108-2025: Updated VAT-Exempt Drug List for Cancer, Diabetes, Hypertension, Kidney Disease, Mental Illness, Tuberculosis, and High Cholesterol

RMC No. 108-2025 updates the FDA-endorsed VAT-exempt drug list for key illnesses, affecting pharmacies, healthcare firms, and corporate tax teams. Businesses selling, importing, prescribing, purchasing, reimbursing, or accounting for qualified medicines must immediately validate their product master files, invoices, VAT treatment, and reimbursement rules against the updated VAT-exempt drug list endorsed by the Food and […]

RMC No. 25-2025: FDA Updates to VAT-Exempt Medicines for Diabetes, Hypertension, High Cholesterol, and Mental Illness

RMC No. 25-2025 confirms FDA updates to VAT-exempt medicines for diabetes, hypertension, high cholesterol, and mental illness under TRAIN and CREATE. Businesses selling, purchasing, distributing, or accounting for medicines covered by the FDA’s updated VAT-exempt list must immediately review their product master files, invoicing settings, and VAT treatment because the VAT exemption takes effect upon […]

RMC No. 131-2024: Updated VAT-Exempt Medicine List for Cancer, Diabetes, and Mental Illness Products

RMC No. 131-2024 updates the VAT-exempt medicine list for cancer, diabetes, and mental illness products, with effectivity tied to FDA publication. Businesses selling, dispensing, importing, distributing, or accounting for qualified medicines must immediately check the latest FDA-published list of VAT-exempt medicines because the VAT exemption under the CREATE Act takes effect based on the FDA’s […]

RMC No. 100-2024: FDA-Endorsed Updates to VAT-Exempt Medicines for Cancer, Diabetes, Hypertension, Kidney Disease, Mental Illness, and Tuberculosis

RMC No. 100-2024 publishes FDA updates to VAT-exempt medicines and confirms exemption applies from the FDA publication date of the updated list. Businesses selling, purchasing, prescribing, distributing, or accounting for covered medicines must immediately check whether their products are included in the updated FDA-endorsed list of VAT-exempt products, because VAT exemption under RMC No. 100-2024 […]

RMC No. 34-2024: FDA Updates to VAT-Exempt Medicines for Cancer, Hypertension, and Mental Illness Under TRAIN and CREATE

RMC No. 34-2024 confirms FDA updates to VAT-exempt medicines for cancer, hypertension, and mental illness, with effect from FDA publication. Businesses selling medicines for cancer, hypertension, and mental illness must immediately check the latest Food and Drug Administration updates to the VAT-exempt product list because VAT exemption takes effect on the date the FDA publishes […]

RMC No. 17-2024: Updated VAT-Exempt Medicines List for Cancer, Diabetes, Hypertension, Kidney Disease, Mental Illness, and Tuberculosis

RMC No. 17-2024 updates VAT-exempt medicines for key diseases, including inclusions and a hypertension medicine deletion tied to FDA publication. Pharmaceutical companies, drugstores, hospitals, clinics, and VAT-registered sellers of medicines must immediately verify whether the medicines they sell are affected by the latest FDA-endorsed updates to the VAT-exempt medicines list. RMC No. 17-2024 publishes the […]

RMC No. 72-2023: Updated VAT-Exempt Medicines List for Cancer, Diabetes, Hypertension and Other Conditions

RMC No. 72-2023 updates the VAT-exempt medicines list, affecting cancer, diabetes, hypertension and other medicines sold by healthcare businesses. Pharmacies, hospitals, clinics, medicine distributors, and VAT-registered healthcare businesses must immediately review whether their medicine master lists, point-of-sale systems, invoices, and tax coding reflect the latest FDA-endorsed updates to the VAT-exempt medicines list. RMC No. 72-2023 […]

RMC No. 42-2023: VAT-Exempt Medicines List Updated for FDA-Endorsed Products Under TRAIN and CREATE

RMC No. 42-2023 confirms FDA-endorsed updates to VAT-exempt medicines and applies exemption from FDA publication of the updated list. Pharmacies, hospitals, clinics, drug distributors, importers, and accounting teams dealing with medicines for cancer, diabetes, kidney disease, mental illness, tuberculosis, high cholesterol, and hypertension should immediately verify whether their products are covered by the FDA-endorsed updates […]

RMC No. 19-2023: VAT Exemption Updates for FDA-Endorsed Medicines and Medical Devices Under TRAIN and CREATE

RMC No. 19-2023 confirms FDA-endorsed VAT-exempt medicine and medical device updates, with CREATE Act exemption effective from FDA publication date. Businesses selling, purchasing, importing, prescribing, distributing, or accounting for VAT-exempt medicines and medical devices must verify whether their products are included in the Food and Drug Administration’s updated VAT-exempt list, because VAT exemption under the […]